Soleno Therapeutics (id:5920 SLNO)
57.78 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 1:04:58 PM)
Exchange closed, opens in 1 day 20 hours
5.05 USD (5.05%)
11.54 USD (11.54%)
6.10 USD (6.10%)
38.96 USD (38.96%)
99.38 USD (99.38%)
155.10 USD (155.10%)
-80.30 USD (-80.30%)
-84.89 USD (-84.89%)
About Soleno Therapeutics
Market Capitalization 2.23B
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.
| Headquarters (address) |
203 Redwood Shores Parkway Redwood City 94065 CA United States |
| Phone | 650 213 8444 |
| Website | https://soleno.life |
| Employees | 33 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | SLNO |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 26.38 - 59.75 |
| Market Capitalization | 2.23B |
| P/E trailing | -24.48 |
| P/E forward | -22.75 |
| Price/Book | 8.01 |
| Beta | -1.44 |
| EPS | -2.79 |
| EPS United States (ID:6, base:3399) | 24.27 |